ContraVir Pharmaceuticals’ (CTRV) “Buy” Rating Reiterated at Maxim Group
ContraVir Pharmaceuticals Inc (NASDAQ:CTRV)‘s stock had its “buy” rating restated by equities research analysts at Maxim Group in a research report issued on Thursday. They presently have a $4.00 target price on the biopharmaceutical company’s stock. Maxim Group’s price objective would suggest a potential upside of 75.82% from the company’s current price.
ContraVir Pharmaceuticals (NASDAQ:CTRV) traded up 17.9133% during mid-day trading on Thursday, hitting $2.3111. 25,774,272 shares of the stock traded hands. ContraVir Pharmaceuticals has a 52 week low of $0.76 and a 52 week high of $2.65. The firm’s 50-day moving average price is $1.14 and its 200-day moving average price is $1.06. The firm’s market cap is $124.00 million.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Prospera Financial Services Inc raised its position in ContraVir Pharmaceuticals by 0.6% in the second quarter. Prospera Financial Services Inc now owns 178,550 shares of the biopharmaceutical company’s stock valued at $186,000 after buying an additional 1,000 shares in the last quarter. Vanguard Group Inc. raised its position in ContraVir Pharmaceuticals by 8.7% in the second quarter. Vanguard Group Inc. now owns 915,369 shares of the biopharmaceutical company’s stock valued at $952,000 after buying an additional 73,135 shares in the last quarter. Finally, Teachers Advisors Inc. raised its position in ContraVir Pharmaceuticals by 95.2% in the second quarter. Teachers Advisors Inc. now owns 289,919 shares of the biopharmaceutical company’s stock valued at $1,102,000 after buying an additional 141,368 shares in the last quarter.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/13/contravir-pharmaceuticals-ctrv-buy-rating-reaffirmed-at-maxim-group.html
About ContraVir Pharmaceuticals
ContraVir Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development of virology drugs to treat diseases of unmet needs, such as herpes zoster and hepatitis B (HBV). It is developing targeted antiviral therapies with over two drug candidates in clinical studies. Its FV-100 is an orally available, small molecule, nucleoside analogue pro-drug of CF-1743 that it is developing for the treatment of herpes zoster, which is an infection caused by the reactivation of varicella zoster virus or VZV.
Receive News & Ratings for ContraVir Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraVir Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.